In addition, strategies such as using LODER‐driven siG12D to inhibit KRAS expression or covalent inhibitors of KRASG12C, such as ARS‐853, have demonstrated inhibition of mutant Kras‐driven signaling and tumor growth in preclinical models [130]. This evidence concerns the gene KRAS and neoplasm.